Developed by DRDO, 2-DG has been granted permission by DCGI for emergency use as adjunct therapy in moderate to severe COVID-19 patients.

Developed by DRDO, 2-DG has been granted permission by DCGI for emergency use as adjunct therapy in moderate to severe COVID-19 patients.